10:32 AM EST, 03/05/2024 (MT Newswires) -- AbbVie's ( ABBV ) Allergan Aesthetics said Tuesday that the Food and Drug Administration approved Juvederm Voluma XC for adults over 21 to improve moderate to severe temple hollowing.

Juvederm Voluma XC is a hyaluronic acid dermal filler that is approved for injection and results can last up to 13 months with optimal treatment, according to the company.

Allergan Aesthetics said it will conduct a product training program for providers as per the requirements of the FDA and the program will cover facial anatomy, patient selection, safe injection and complications.

Allergan Aesthetics expects Juvederm Voluma XC for temple treatment to be available by year-end.

AbbVie ( ABBV ) shares were up 1.2% in recent trading.

Price: 179.25, Change: +2.20, Percent Change: +1.24